Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
5.82
+0.09 (1.57%)
Apr 29, 2026, 3:04 PM CST
SHE:300039 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 786.25 | 980.71 | 593.31 | 601.94 | 694.69 | 1,345 |
Short-Term Investments | - | - | 924.87 | - | - | 58.32 |
Trading Asset Securities | 305.02 | 58.53 | 180.02 | 150.01 | 136.07 | 51.26 |
Cash & Short-Term Investments | 1,091 | 1,039 | 1,698 | 751.95 | 830.76 | 1,455 |
Cash Growth | -44.58% | -38.80% | 125.84% | -9.49% | -42.88% | -0.23% |
Accounts Receivable | 424.78 | 409.79 | 471.99 | 529.32 | 530.33 | 567.99 |
Other Receivables | 1.32 | 0.34 | 34.51 | 10.34 | 35.77 | 46.77 |
Receivables | 426.1 | 410.13 | 506.51 | 539.67 | 566.09 | 614.76 |
Inventory | 189.02 | 200.41 | 187.85 | 171.79 | 160.8 | 165.14 |
Other Current Assets | 350.44 | 588.31 | 22.81 | 11.47 | 16.77 | 19.99 |
Total Current Assets | 2,057 | 2,238 | 2,415 | 1,475 | 1,574 | 2,254 |
Property, Plant & Equipment | 273.26 | 280.52 | 267.85 | 290.09 | 304.66 | 307.78 |
Long-Term Investments | 1,399 | 1,166 | 1,624 | 2,730 | 1,312 | 711.06 |
Goodwill | - | - | - | - | 9.04 | 13.79 |
Other Intangible Assets | 162.27 | 163.57 | 168.8 | 45.11 | 44.23 | 42.9 |
Long-Term Deferred Tax Assets | 19.79 | 21.47 | 29.44 | 31.61 | 18.26 | 15.1 |
Long-Term Deferred Charges | 2.61 | 2.66 | 2.44 | 0.21 | 0.32 | - |
Other Long-Term Assets | 1,176 | 906.46 | 11.03 | 7.64 | 996.49 | 10.75 |
Total Assets | 5,090 | 4,778 | 4,518 | 4,580 | 4,259 | 3,356 |
Accounts Payable | 127.53 | 93.61 | 99.37 | 134.85 | 91.01 | 75.02 |
Accrued Expenses | 0.59 | 1.23 | 26.46 | 23.27 | 29.69 | 15.92 |
Short-Term Debt | 4.73 | 4.08 | 5.42 | - | - | - |
Current Income Taxes Payable | 23.67 | 37.57 | 31.62 | 41.08 | 35.54 | 3.47 |
Current Unearned Revenue | 12.11 | 12.44 | 18.29 | 45.69 | 40.04 | 2.88 |
Other Current Liabilities | 16.8 | 17.99 | 51.15 | 89.96 | 99.67 | 93.39 |
Total Current Liabilities | 185.43 | 166.91 | 232.3 | 334.85 | 295.96 | 190.68 |
Long-Term Unearned Revenue | 46.58 | 44.26 | 48.03 | 43.26 | 39.51 | 47.16 |
Long-Term Deferred Tax Liabilities | 182.42 | 148.47 | 135.11 | 168.71 | 162.77 | 73.06 |
Total Liabilities | 414.43 | 359.64 | 415.45 | 546.82 | 498.24 | 310.9 |
Common Stock | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Additional Paid-In Capital | 8.62 | 8.62 | 8.62 | 8.62 | 8.62 | 8.62 |
Retained Earnings | 2,613 | 2,548 | 2,323 | 2,050 | 1,785 | 1,577 |
Comprehensive Income & Other | 1,008 | 815.43 | 724.5 | 926.33 | 921.98 | 413.53 |
Total Common Equity | 4,676 | 4,418 | 4,102 | 4,031 | 3,762 | 3,045 |
Minority Interest | 0.27 | 0.39 | 0.97 | 1.64 | -0.72 | -0 |
Shareholders' Equity | 4,676 | 4,419 | 4,103 | 4,033 | 3,761 | 3,045 |
Total Liabilities & Equity | 5,090 | 4,778 | 4,518 | 4,580 | 4,259 | 3,356 |
Total Debt | 4.73 | 4.08 | 5.42 | - | - | - |
Net Cash (Debt) | 1,087 | 1,035 | 1,693 | 751.95 | 830.76 | 1,455 |
Net Cash Growth | -44.65% | -38.85% | 125.12% | -9.49% | -42.88% | 2.28% |
Net Cash Per Share | 1.04 | 0.99 | 1.62 | 0.72 | 0.79 | 1.39 |
Filing Date Shares Outstanding | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Total Common Shares Outstanding | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Working Capital | 1,871 | 2,071 | 2,183 | 1,140 | 1,278 | 2,064 |
Book Value Per Share | 4.47 | 4.22 | 3.92 | 3.85 | 3.60 | 2.91 |
Tangible Book Value | 4,513 | 4,255 | 3,933 | 3,986 | 3,708 | 2,988 |
Tangible Book Value Per Share | 4.31 | 4.07 | 3.76 | 3.81 | 3.55 | 2.86 |
Buildings | - | - | 386.31 | 383.04 | 372.25 | 342.91 |
Machinery | - | - | 425.35 | 441.06 | 427.9 | 407.9 |
Construction In Progress | - | - | 1.23 | 0.52 | 6.18 | 34.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.